Background
Facial skin pores (FSP) are common and benign signs that generate frequent esthetic concerns or complaints. Despite their worldwide prevalence, related literature remains scarce. Hence, a ...new device has been developed and applied to validating studies, aiming at best describing FSP as they are self‐perceived, i.e. their anatomic features, their possible alterations with age and their appearance after application of a make‐up product.
Methods
Dermascore+® is an imaging device dedicated to a direct observation and acquisition of various characteristics of the skin surface. Images are captured under a high magnification and under different lighting configurations, to highlight the skin relief, based upon parallel polarized images. Dedicated software allows FSP to being detected and their morphological parameters to being extracted and computed. By measuring each detected FSP in a given region of interest, a statistically significant impact of both age and an applied cosmetic product upon their morphological features can be observed and quantified.
Results
Although the size and density of FSP are not affected by aging, their shape becomes elongated. A few tested make up products show variable effects that closely correlate with visual assessments made by trained estheticians.
Conclusion
The shape of FSP present on cheeks shows age‐related changes, toward a more elongated aspect, likely linked to a progressively altered (more isotropic) skin surface micro‐relief. The new tool Dermascore+® allows foundations to being rapidly differentiated and screened according to their variable effects upon the visual appearance through instrumental, objective depiction of FSP.
•We model the opening and closure of a Cretaceous northern Andean back-arc basin.•Mantle flow reconstructions are consistent with mid-mantle structure from tomography.•This scenario is consistent ...with rollback along the extremities of wide subduction zones.
A complex history of subduction, back-arc basin formation, terrane accretion and transpressional shearing characterizes the evolution of the Caribbean and northern South American margin since Jurassic times. Quantitative plate tectonic reconstructions of the area do not include Jurassic-Cretaceous back-arc terranes of which there are both geological and geophysical observations. We developed a revised plate tectonic reconstruction based on geological observations and seismic tomography models to constrain the Jurassic-Cretaceous subduction history of eastern Panthalassa, along the western margin of the Caribbean region. This reconstruction considers the opening of a Northern Andean back-arc basin at 145 Ma, the Quebradagrande back-arc, closing at 120 Ma and followed by terrane accretion and northward translation along the South American margin starting at 100 Ma. This kinematic reconstruction is tested against two previously published tectonic reconstructions via coupling with global numerical mantle convection models using CitcomS. A comparison of modelled versus tomographically imaged mantle structure reveals that subduction outboard of the South American margin, lacking in previous tectonic models, is required to reproduce mid-mantle positive seismic anomalies imaged in P- and S-wave seismic tomography beneath South America, 500–2000 km in depth. Furthermore, we show that this subduction zone is likely produced by a back-arc basin that developed along the northern Andes during the Cretaceous via trench roll-back from 145 Ma and was closed at 100 Ma. The contemporaneous opening of the Quebradagrande back-arc basin with the Rocas Verdes back-arc basin in the southern Andes is consistent with a model that invokes return flow of mantle material behind a retreating slab and may explain why extension along the Peruvian and Chilean sections of the Andean margin did not experience full crustal break-up and back-arc opening during the late Jurassic-early Cretaceous Period.
The peritoneum is one of the most frequent sites of recurrent gastric carcinoma after curative treatment, despite the administration of pre- and/or postoperative systemic chemotherapy. Indeed, the ...prognosis of peritoneal carcinomatosis from gastric carcinoma continues to be poor, with a median survival of less than one year with systemic chemotherapy. Whereas the prognosis of peritoneal carcinomatosis from colorectal cancer has changed with the development of locally administered hyperthermic intraperitoneal chemotherapy (HIPEC), survival results following carcinomatosis from gastric cancer remain disappointing, yielding a 5-year survival rate of less than 20%. Innovative surgical therapies such as intraperitoneal immunotherapy therefore need to be developed for the immediate postoperative period after complete cytoreductive surgery. In a recent randomised study, a clinical effect was obtained after intraperitoneal infusion of catumaxomab in patients with malignant ascites, notably from gastric carcinoma. Catumaxomab, a nonhumanized chimeric antibody, is characterized by its unique ability to bind to three different types of cells: tumour cells expressing the epithelial cell adhesion molecule (EpCAM), T lymphocytes (CD3) and also accessory cells (Fcγ receptor). Because the peritoneum is an immunocompetent organ and up to 90% of gastric carcinomas express EpCAM, intraperitoneal infusion of catumaxomab after complete resection of all macroscopic disease (as defined in the treatment of carcinomatosis from colorectal cancer) could therefore efficiently treat microscopic residual disease.
The aim of this randomized phase II study is to assess 2-year overall survival after complete resection of limited carcinomatosis synchronous with gastric carcinoma, followed by an intraperitoneal infusion of catumaxomab with different total doses administered in each of the 2 arms. Close monitoring of peri-opertive mortality, morbidity and early surgical re-intervention will be done with stopping rules. Besides this analysis, translational research will be conducted to determine immunological markers of catumaxomab efficacy and to correlate these markers with clinical efficacy.
Aeolus Rayleigh‐channel winds in cloudy conditions Marseille, Gert‐Jan; Kloe, Jos; Dabas, Alain ...
Quarterly journal of the Royal Meteorological Society,
October 2023 Part B, Volume:
149, Issue:
757
Journal Article
Peer reviewed
Open access
Aeolus carried the first Doppler wind lidar to measure wind profiles from space. Aeolus was a European Space Agency explorer mission with the objective to retrieve winds data from the collected ...atmospheric return signal that is the result of Mie and Rayleigh scattering of laser emitted light by atmospheric molecules and particulates. During the course of the mission the quality of Aeolus winds measured in clear‐air conditions from Rayleigh‐channel‐collected data, so called Rayleigh‐clear winds, improved substantially. The same is true for winds measured in cloudy and aerosol‐rich atmospheric conditions from Mie‐channel‐collected data, the so‐called Mie‐cloudy winds. For the latter conditions, good quality winds can in principle also be obtained from Rayleigh‐channel‐collected data, the so‐called Rayleigh‐cloudy winds, if contamination of the purely molecular signal by Mie scattering is well addressed. We assess a linear and nonlinear correction for Mie contamination, the latter with the aid of numerical weather prediction model data for determing the correction parameters. We show that the nonlinear correction is able to provide unbiased Rayleigh‐cloudy winds. This makes Rayleigh‐cloudy winds suitable for use in numerical weather prediction, but also for direct comparison with other wind observations obtained in cloudy conditions, such as atmospheric motion wind vectors.
One orbit of Aeolus horizontal line‐of‐sight wind velocity (m·$$ \cdotp $$s−1$$ {}^{-1} $$) retrieved from Rayleigh‐channel‐measured data in cloudy conditions on August 15, 2019, around 0253 UTC.
IntroductionIdiopathic pulmonary fibrosis (IPF) is the most common and severe interstitial lung disease (ILD). It is a progressive disease that requires a regular follow-up: clinical examination, ...pulmonary function testing (PFT) and CT scan, which is performed yearly in France. These exams have two major disadvantages: patients with severe dyspnoea have difficulties to perform PFT and repeated CT scans expose to high dose of radiations. Considering these limits, it would be relevant to develop new tools to monitor the progression of IPF lesions. Three main signs have been described in ILD with lung ultrasound (LUS): the number of B lines, the irregularity and the thickening of the pleural line. Cross-sectional studies already correlated the intensity of these signs with the severity of fibrosis lesions on CT scan in patients with IPF, but no prospective study described the evolution of the three main LUS signs, nor the correlation between clinical evaluation, PFT and CT scan. Our hypothesis is that LUS is a relevant tool to highlight the evolution of pulmonary lesions in IPF. The main objective of our study is to show an increase in one or more of the three main LUS signs (total number of B lines, pleural line irregularity score and pleural line thickness) during the follow-up.MethodsThOracic Ultrasound in Idiopathic Pulmonary Fibrosis Evolution is a French prospective, multicentric and non-interventional study. Every 3 months, patients with IPF will have a clinical examination, PFT and LUS. CT data will be collected if the CT scan is performed within 3 months before the inclusion; the second CT scan will be performed from 9 to 12 months after the inclusion. The presence, location and severity of LUS signs will be recorded for each patient, and their correlation with clinical, functional and CT scan evolution will be evaluated. 30 patients will be enrolled.Ethics and disseminationThe protocol was approved by the French Research Ethics Committee (Comité de Protection des Personnes SUD OUEST ET OUTRE MER II, reference RIPH3-RNI19-TOUPIE) on 11 April 2019. Results will be disseminated via peer-reviewed publication and presentation at international conferences.Trial registration numberNCT03944928;Pre-results.
Proton induced nuclear reactions were measured with stacked-foil technique on natural uranium targets in the energy range from 211 to 2,530 MeV at the Saturne II synchrocyclotron at the Laboratoire ...National Saturne/Saclay (France). Twenty-three reactions were determined by means of off-line
γ
-spectrometry. The obtained excitation functions have been compared with the earlier published data and the theoretical model INCL4 + ABLA.
Purpose 40% of triple-negative breast cancer (TNBC) do not express claudin-1, a major constituent of tight junction. Patients with these "claudin-1-low" tumors present a higher relapse incidence. A ...major challenge in oncology is the development of innovative therapies for such poor prognosis tumors. In this context, we study the anticancer effects of #226;2-TGZ, a compound derived from troglitazone (TGZ), on cell models of these tumors. Methods and results In MDA-MB-231 and Hs578T "claudin-1-low" TNBC cells, DELTA2-TGZ treatment induced claudin-1 protein expression and triggered apoptosis as measured by FACS analysis (annexin V/PI co-staining). Interestingly, in the non-tumorigenic human breast epithelial cell line MCF-10A, the basal level of claudin-1 was not modified following DELTA2-TGZ treatment, which did not induce apoptosis. Furthermore, claudin-1-transfected MDA-MB-231 and Hs578T cells displayed a significant increase of cleaved PARP-1 and caspase 7, caspase 3/7 activities, and TUNEL staining. RNA interference was performed in order to inhibit DELTA2-TGZ-induced claudin-1 expression in both the cells. In absence of claudin-1, a decrease of cleaved PARP-1 and caspase 7 and caspase 3/7 activities were observed in MDA-MB-231 but not in Hs578T cells. Conclusion Claudin-1 overexpression and DELTA2-TGZ treatment are associated to apoptosis in MDA-MB-231 and Hs578T "claudin-1-low" TNBC. Moreover, in MDA-MB-231 cells, claudin-1 is involved in the pro-apoptotic effect of DELTA2-TGZ. Our results suggest that claudin-1 re-expression could be an interesting therapeutic strategy for "claudin-1-low" TNBC.
PDF
